Table 2. Association between rs2660845 and asthma exacerbation in late-onset GoSHARE(a) individuals 12 months before being on montelukast.

Study	GoSHARE(a) (n = 953)
OR (95% CI)	0.85 (0.641–1.127)
P-value	0.6388

Odds of exacerbation rate on montelukast using an additive model adjusted for age, gender, age at 1st montelukast prescription or age at asthma onset and BMI when significant and available.

GoSHARE(a): individuals with age at first salbutamol, age at first inhaled corticosteroid and age at first montelukast prescription, all three over 18 years old.